Paul A Friedman - Net Worth and Insider Trading
Paul A Friedman Net Worth
The estimated net worth of Paul A Friedman is at least $191 Million dollars as of 2024-05-02. Paul A Friedman is the Director of Madrigal Pharmaceuticals Inc and owns about 841,275 shares of Madrigal Pharmaceuticals Inc (MDGL) stock worth over $177 Million. Paul A Friedman is also the Director of Incyte Corp and owns about 270,531 shares of Incyte Corp (INCY) stock worth over $14 Million. Details can be seen in Paul A Friedman's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Paul A Friedman has not made any transactions after 2024-04-08 and currently still holds the listed stock(s).
Transaction Summary of Paul A Friedman
Paul A Friedman Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paul A Friedman owns 6 companies in total, including Prelude Therapeutics Inc (PRLD) , Incyte Corp (INCY) , and Alexion Pharmaceuticals Inc (ALXN) among others .
Click here to see the complete history of Paul A Friedman’s form 4 insider trades.
Insider Ownership Summary of Paul A Friedman
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | 2020-09-24 | director |
| INCY | Incyte Corp | 2019-08-06 | director & Chief Executive Officer |
| ALXN | Alexion Pharmaceuticals Inc | 2020-05-14 | director |
 | | 2024-04-08 | director & Chief Executive Officer |
| | 2014-04-10 | director |
| | 2014-05-12 | director |
Paul A Friedman Latest Holdings Summary
Paul A Friedman currently owns a total of 2 stocks. Among these stocks, Paul A Friedman owns 841,275 shares of Madrigal Pharmaceuticals Inc (MDGL) as of April 8, 2024, with a value of $177 Million and a weighting of 92.58%. Paul A Friedman also owns 270,531 shares of Incyte Corp (INCY) as of August 6, 2019, with a value of $14 Million and a weighting of 7.42%.
Latest Holdings of Paul A Friedman
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MDGL | Madrigal Pharmaceuticals Inc | 2024-04-08 | 841,275 | 210.19 | 176,827,592 |
| INCY | Incyte Corp | 2019-08-06 | 270,531 | 52.35 | 14,162,298 |
Holding Weightings of Paul A Friedman
Paul A Friedman Form 4 Trading Tracker
According to the SEC Form 4 filings, Paul A Friedman has made a total of 2 transactions in Madrigal Pharmaceuticals Inc (MDGL) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Madrigal Pharmaceuticals Inc is the sale of 26,270 shares on April 8, 2024, which brought Paul A Friedman around $6 Million.
According to the SEC Form 4 filings, Paul A Friedman has made a total of 1 transactions in Incyte Corp (INCY) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Incyte Corp is the sale of 100,000 shares on August 6, 2019, which brought Paul A Friedman around $8 Million.
Insider Trading History of Paul A Friedman
- 1
Paul A Friedman Trading Performance
GuruFocus tracks the stock performance after each of Paul A Friedman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul A Friedman is 27.76%. GuruFocus also compares Paul A Friedman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul A Friedman within 3 months outperforms 8 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Paul A Friedman's insider trading performs compared to the benchmark.
Performance of Paul A Friedman
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 11.32 | | | | | |
| Relative Return to S&P 500(%) | 7.52 | | | | | |
Paul A Friedman Ownership Network
Paul A Friedman Owned Company Details
What does Prelude Therapeutics Inc do?
Who are the key executives at Prelude Therapeutics Inc?
Paul A Friedman is the director of Prelude Therapeutics Inc. Other key executives at Prelude Therapeutics Inc include director & President & CEO Krishna Vaddi , Chief Legal Counsel & Corp Sec. Bryant David Lim , and Chief Financial Officer Laurent Chardonnet .
Prelude Therapeutics Inc (PRLD) Insider Trades Summary
Over the past 18 months, Paul A Friedman made no insider transaction in Prelude Therapeutics Inc (PRLD). Other recent insider transactions involving Prelude Therapeutics Inc (PRLD) include a net purchase of 32,944 shares made by Krishna Vaddi , a net purchase of 15,000 shares made by Laurent Chardonnet , and a net purchase of 869,565 shares made by Orbimed Advisors Llc .
In summary, during the past 3 months, insiders sold 0 shares of Prelude Therapeutics Inc (PRLD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 13,280 shares of Prelude Therapeutics Inc (PRLD) were sold and 1,789,474 shares were bought by its insiders, resulting in a net purchase of 1,776,194 shares.
Prelude Therapeutics Inc (PRLD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Prelude Therapeutics Inc Insider Transactions
Paul A Friedman Mailing Address
Above is the net worth, insider trading, and ownership report for Paul A Friedman. You might contact Paul A Friedman via mailing address: C/o Incyte Corporation, 1801 Augustine Cut-off, Wilmington De 19803.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
